{"entity":{"id":"guardant-reveal","kind":"drug","name":"Guardant Reveal","aka":[],"tldr":"A blood test for leftover cancer after surgery that needs no tumour sample, so results come faster than tumour-informed tests.","summary":"Guardant Reveal launched in 2021 as the first tissue-free MRD test, initially for stage II-III colorectal cancer, with Medicare coverage for colorectal cancer surveillance and later breast and lung indications. Tumour-naive design gives a result within about a week of surgery and suits patients whose tissue is unavailable, at the cost of somewhat lower sensitivity than bespoke tumour-informed panels such as Signatera. Published colorectal data show ctDNA positivity after surgery carries a high risk of recurrence, and serial negative results are strongly reassuring. It is a laboratory-developed test under CLIA.","status":"established","asOf":"2026-09-10","links":[{"label":"Guardant Reveal (page moved; nearest live section)","url":"https://guardanthealth.com/"}],"tags":["test"],"related":["signatera","radar-mrd"],"cancers":["colorectal","breast-hr-positive","nsclc"],"sections":[],"technologies":["mrd-testing","liquid-biopsy","methylation-profiling"],"targets":[],"drugs":[],"companies":["guardant-health"],"institutions":[],"pathways":[],"terms":["mrd","ctdna"],"trials":["nct07802626"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["What a result means: ctDNA detected after surgery means a high chance of recurrence and a case for closer follow-up or adjuvant therapy; not detected is reassuring but not a guarantee.","Colorectal cancer: a tumour-naive residual disease assay combining methylation and mutation signal, used in the same postoperative setting as the tumour-informed tests but without needing tumour tissue; the randomised evidence in colorectal cancer is for tumour-informed assays (Tie 2022), so the equivalence is inferred rather than shown."],"brand":"Guardant Reveal","modality":"Tumour-naive ctDNA minimal residual disease test (methylation and genomic)","mechanism":"Blood-only assay combining somatic variant detection with cancer-specific methylation signals, so no tumour tissue is needed to design the test.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/guardant-reveal/","neighbours":{"drug":[{"id":"radar-mrd","kind":"drug","name":"RaDaR","route":"/drugs/radar-mrd/"},{"id":"signatera","kind":"drug","name":"Signatera","route":"/drugs/signatera/"}],"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"technology":[{"id":"cea-surveillance-colorectal","kind":"technology","name":"CEA surveillance after colorectal cancer surgery","route":"/technologies/cea-surveillance-colorectal/"},{"id":"methylation-profiling","kind":"technology","name":"DNA methylation profiling","route":"/technologies/methylation-profiling/"},{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"company":[{"id":"guardant-health","kind":"company","name":"Guardant Health","route":"/companies/guardant-health/"}],"term":[{"id":"ctdna","kind":"term","name":"Circulating tumour DNA (ctDNA)","route":"/terms/ctdna/"},{"id":"mrd","kind":"term","name":"Minimal / molecular residual disease (MRD)","route":"/terms/mrd/"},{"id":"tumour-informed-assay","kind":"term","name":"Tumour-informed versus tumour-naive ctDNA assays","route":"/terms/tumour-informed-assay/"}],"trial":[{"id":"nct07802626","kind":"trial","name":"Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA Testing","route":"/trials/nct07802626/"}],"roadmap":[{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/"},{"id":"diagnostics-roadmap","kind":"roadmap","name":"Diagnostics roadmap: stains → gene panels → blood tests that decide treatment","route":"/roadmaps/diagnostics-roadmap/"}],"biomarker":[{"id":"ctdna-mrd-positive","kind":"biomarker","name":"ctDNA MRD positivity (molecular residual disease after curative treatment)","route":"/biomarkers/ctdna-mrd-positive/"}]}}